Published August 17, 2026Updated October 30, 2026

Mounjaro vs Zepbound Cost: Which One Insurance Pays For

Mounjaro and Zepbound are both tirzepatide with different FDA approvals. We compare indication, price and insurance coverage, and which one fits you.

By Ruth Calder, Enforcement Editor

Our methodology sets out how these guides get researched and kept current.

Looking for a provider? Our 2026 comparison of the leading GLP-1 telehealth sellers is a click away.

Compare Providers →

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

If you have read our Ozempic vs Wegovy guide, this one will look familiar: the same story, told on the tirzepatide side of the GLP-1 market. Mounjaro and Zepbound are both tirzepatide and both made by Eli Lilly. They differ in FDA approvals, pricing and insurance, not in chemistry.

Below we cover what differs between Mounjaro and Zepbound, who should take which, and how the compounded tirzepatide market changes the math in 2026.

Key Takeaways

  • Same active ingredient (tirzepatide), same manufacturer (Eli Lilly).
  • Different FDA approvals: type 2 diabetes is Mounjaro's. Zepbound holds weight management, and sleep apnea in obesity.
  • Same doses: Both go from 2.5 mg to 15 mg weekly via the same titration schedule.
  • Similar list prices: Zepbound lists at up to ~$1,086/month and Mounjaro's list price is close to it. Lilly also sells Zepbound for cash from $299/month, which usually makes it the cheapest alternative to Mounjaro for anyone who qualifies on weight.
  • Insurance coverage is much better for Mounjaro (diabetes patients) than for Zepbound (obesity patients).
  • Compounded tirzepatide availability has been more volatile than semaglutide due to FDA shortage list changes.

Same Drug, Two Names

Eli Lilly developed tirzepatide, a dual GIP/GLP-1 receptor agonist that acts on both receptors. Activating two incretin pathways at once is the reason it outperforms single-pathway GLP-1 drugs such as semaglutide on weight loss. (For the head-to-head, see Semaglutide vs Tirzepatide.)

Lilly pursued two FDA approvals for the same molecule:

  • Mounjaro: Approved May 2022 for type 2 diabetes
  • Zepbound: November 2023 brought the weight-management approval; December 2024 added obstructive sleep apnea in adults who have obesity

The pharmacology is identical. Patients sometimes worry that the two products use different formulations or strengths. They don't. Both labels list the same strengths and the same presentations, so the difference between a Mounjaro pen and a Zepbound pen is the labeling and packaging. (What differs is how Lilly sells them, which we'll get to.)

See the full molecule background in our tirzepatide drug guide.

What's Actually Different

1. FDA Indication

  • Mounjaro: glycemic control, for adults with type 2 diabetes mellitus, and for children with it from age 10, alongside diet and exercise. It also carries a cardiovascular indication: fewer heart attacks, strokes and cardiovascular deaths in diabetic adults whose cardiovascular risk is high.
  • Zepbound: weight management over the long term, in adults who have obesity, or overweight plus a weight-related comorbidity. Its trials enrolled at BMI ≥30, or BMI ≥27 with a comorbidity. A second indication, added late in 2024, covers moderate-to-severe obstructive sleep apnea in adults who have obesity.

This matters for two reasons. First, your prescribing doctor must match the indication to your diagnosis. Second, insurance reimbursement is tied to the indication: covered for diabetes, often not covered for obesity.

2. Dosing: Identical

Both drugs use the exact same titration schedule:

2. Dosing: Identical
WeekDose
1–42.5 mg
5–85 mg
9–127.5 mg
13–1610 mg
17–2012.5 mg
21+15 mg (maximum)

Unlike Ozempic vs Wegovy (where the maintenance doses differ), Mounjaro and Zepbound max out at the same 15 mg dose. That makes the clinical decision easier: there's no "more powerful version" to chase.

3. Packaging and Format

  • Both labels list the same presentations: pre-filled single-dose pens, single-dose vials, multi-dose vials and 4-dose KwikPens.
  • Zepbound is the one Lilly sells directly to cash-pay patients: single-dose vials (introduced in 2024) and the KwikPen, through LillyDirect.

The cash-pay route matters because LillyDirect prices sit well below list: 2.5 mg costs $299 a month and 5 mg costs $399, and every higher dose is $449 provided each refill arrives within 45 days ($499–$699 when a refill runs late). This was Lilly's response to the compounded tirzepatide market.

4. Pricing

4. Pricing
SourceMonthly cost (typical)
Zepbound list priceUp to ~$1,086
Zepbound KwikPen or vial via LillyDirect (2.5 mg starter)$299
Zepbound KwikPen or vial via LillyDirect (5 mg)$399
Zepbound KwikPen or vial via LillyDirect (7.5–15 mg, refill within 45 days)$449
Compounded tirzepatide (telehealth)$199–$399

Both brands run manufacturer savings programs that can reduce out-of-pocket costs significantly. If your commercial plan covers Zepbound, the Zepbound Savings Card can bring the single-dose pen down to $25/month; if the plan does not cover it, the card brings the pen to $499/month. The Mounjaro Savings Card works the same way: $25 with coverage, $499 without.

Telehealth sellers that prescribe the brand drugs do not all carry both. Layla and DudeMeds list Mounjaro and Zepbound, Layla on a monthly plan and DudeMeds billed three months up front. AlyveRx lists Mounjaro, and Klinic prescribes Zepbound under its brand name and shows the price before the health questionnaire.

Luvo Health, Nucific and Tomorrow list Zepbound next to their compounded options. KairoRx charges an access fee for Zepbound and bills the medication separately. NuuVim lists brand Zepbound beside compounded tirzepatide, offered as a weekly injection or a daily oral liquid.

5. Insurance Coverage

Same story as Ozempic vs Wegovy. Mounjaro is widely covered by insurance for type 2 diabetes patients. Zepbound coverage for obesity is patchy and often requires prior authorization with strict BMI and comorbidity documentation. Part D plans may cover Zepbound for sleep apnea. For weight management, Medicare Part D patients who qualify can get the Zepbound KwikPen for $50/month under the Medicare GLP-1 Bridge, a temporary program running from July 2026 to the end of 2027; the single-dose pen and vials are not covered.

For a full breakdown of insurance options, see our Cost & Insurance pillar guide.

Compounded Tirzepatide: A Volatile Market

The FDA drug shortage list carried tirzepatide from 2022 until late 2024. This allowed 503A and 503B pharmacies to legally compound tirzepatide for patients whose doctors prescribed it. A robust telehealth industry sprang up, with providers offering compounded tirzepatide for $200–$400/month.

In October 2024, the FDA declared the shortage resolved. Compounders challenged the decision in court, the FDA re-evaluated it and confirmed it in December 2024, and in March 2025 the court denied the compounders' request for a preliminary injunction. The FDA's grace periods for compounders ended that March. The rules have since settled: the FDA says 503B outsourcing facilities may not compound tirzepatide from bulk ingredients, and 503A pharmacies may compound copies of an approved drug only for individual patients, not regularly or in large amounts, unless the prescriber documents a significant difference for that patient (e.g. allergies to inactive ingredients in the brand product).

In practice, compounded tirzepatide is still available through reputable telehealth providers, but the supply is more restricted than compounded semaglutide. Pricing has crept up from the 2024 lows, and not every provider that offered tirzepatide in 2024 still offers it in 2026.

Our best GLP-1 providers ranking flags which providers currently offer compounded tirzepatide and at what dose ranges. Notable options:

  • CoreAge Rx: offers both compounded semaglutide and tirzepatide
  • Henry Meds: tirzepatide available in select states
  • Mochi Health: covers tirzepatide as part of their broader weight management program

The principles in our compounded semaglutide safety guide apply to compounded tirzepatide too.

Side Effects

Because both are the same molecule, the side effect profile does not vary between the two names:

  • Common (>10%): fatigue, injection site reactions, and gut effects (nausea, decreased appetite, diarrhea, constipation, vomiting, dyspepsia, abdominal pain)
  • Less common: hair loss, gallbladder disease, allergic reactions, and hypoglycemia (mostly in patients who also have diabetes)
  • Rare but serious: acute kidney injury, pancreatitis, hypersensitivity reactions, severe gastrointestinal disease
  • Boxed warning: thyroid C-cell tumors in rats. Tirzepatide is contraindicated in MEN2, and in anyone who has had medullary thyroid carcinoma or has it in the family

In SURMOUNT-1, adverse events led to discontinuation in 4.3% to 7.1% of tirzepatide patients, depending on dose, vs 2.6% of placebo. Slow titration is the most effective prevention strategy.

Who Should Choose Which?

Choose Mounjaro if you...

  • Have type 2 diabetes (covered by insurance, on-label, lower out-of-pocket)
  • Want the brand-name option and have insurance that covers diabetes drugs
  • Need the cardiovascular and renal protective effects studied in SURPASS trials

Choose Zepbound if you...

  • Don't have diabetes but qualify for weight management indication
  • Have moderate-to-severe obstructive sleep apnea with obesity (FDA-approved indication as of late 2024)
  • Can use the LillyDirect vial program for lower cash-pay pricing
  • Have insurance that specifically covers Zepbound (or have access to the savings card)

Choose compounded tirzepatide if you...

  • Have no insurance coverage for either brand
  • Want the lowest out-of-pocket cost
  • Are comfortable with the regulatory and supply uncertainty of the compounded market
  • Use a verified telehealth provider that names the state-licensed 503A pharmacy filling your prescription

Bottom Line

Mounjaro and Zepbound are functionally identical drugs with different labels for different patient populations. If you have diabetes, your doctor will prescribe Mounjaro and your insurance will probably cover it. If you don't have diabetes and are paying out-of-pocket, the practical decision is between a Zepbound KwikPen or vials via LillyDirect ($299–$449/month within the 45-day refill window) and compounded tirzepatide via a trusted telehealth provider (~$199–$399/month).

For most weight-loss patients, the choice comes down to risk tolerance: brand-name Zepbound offers regulatory certainty and the strongest evidence base, while compounded tirzepatide offers a lower price with somewhat more legal and supply uncertainty.

For the broader picture on which GLP-1 to choose, read our Semaglutide vs Tirzepatide head-to-head. For help estimating your specific costs, use our savings calculator.

Sources & methodology — as of October 2026
  1. 1.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  2. 2.SURPASS-2 Trial — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (Frías JP et al.)— New England Journal of Medicine.PMID: 34170647.
  3. 3.SURPASS-3 Trial — Tirzepatide versus Insulin Degludec in Type 2 Diabetes (Ludvik B et al.)— The Lancet.PMID: 34370970.
  4. 4.SURMOUNT-2 Trial — Tirzepatide for the Treatment of Obesity in People with Type 2 Diabetes (Garvey WT et al.)— The Lancet.PMID: 37385275.
  5. 5.SURMOUNT-3 Trial — Tirzepatide After Intensive Lifestyle Intervention in Adults with Overweight or Obesity (Wadden TA et al.)— Nature Medicine.PMID: 37840095.
  6. 6.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  7. 7.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.

Ready to compare GLP-1 providers?

Trust, support, availability, the medications carried and what they cost — we rank every major telehealth seller on all five, and refresh it each quarter. Nothing padded.

Compare Providers →

Read our methodology · affiliate disclosure · about us